|
Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals, and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.
|
| | | Contact Information | |
Address: |
1000, chemin du Golf
Verdun, Quebec H3E 1H4, Canada
| | Phone: | 514-751-2003 | | Fax: | 514-751-2709 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 3.40 M | | Revenue Growth (1 yr): | 298.60% | | Employees (2008): | 14 | | Employee Growth (1 yr): | (-71.40%) |
|
|
Key People
| | • |
Chairman:
Frédéric Porte
| | • |
Interim President and Interim CEO:
Richard La Rue
| | • |
CFO:
Brian L. Davies
|
|
|
